| 3.4 0.39 (12.96%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.8  |
1-year : | 7.44 |
| Resists | First : | 4.96 |
Second : | 6.36 |
| Pivot price | 4.21 |
|||
| Supports | First : | 2.69 | Second : | 2.24 |
| MAs | MA(5) : | 3.67 |
MA(20) : | 4.44 |
| MA(100) : | 4.01 |
MA(250) : | 16.95 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 14 |
D(3) : | 8.4 |
| RSI | RSI(14): 34.4 |
|||
| 52-week | High : | 128.9 | Low : | 1.91 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PBM ] has closed above bottom band by 11.9%. Bollinger Bands are 60.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.44 - 3.46 | 3.46 - 3.48 |
| Low: | 2.94 - 2.96 | 2.96 - 2.98 |
| Close: | 3.36 - 3.4 | 3.4 - 3.43 |
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Fri, 23 Oct 2026
Psyence Biomedical Ltd. Estimates – NASDAQ:PBM - TradingView
Wed, 21 Oct 2026
An ibogaine manufacturing deal helps unlock Psyence Biomedical (PBM)'s additional PsyLabs investment. - Stock Titan
Thu, 15 Oct 2026
A cashless $8.99M swap expands a shareholder’s stake in Psyence Biomedical (PBM). - Stock Titan
Mon, 28 Sep 2026
Psyence Biomedical Ltd. enters U.S. ibogaine terms - Mugglehead Investment Magazine
Wed, 23 Sep 2026
Psyence BioMed Agrees Up to $5 Million PsyLabs Investment and Forms Texas Ibogaine Unit - Yahoo Finance
Tue, 18 Aug 2026
Psyence Biomedical stock surges on Trump ibogaine announcement - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 13.2 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 14 (K) |
| EPS | -12.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.4 % |
| Return on Equity (ttm) | -58.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.28 |
| PEG Ratio | 0 |
| Price to Book value | 0.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|